NCT05071430View on ClinicalTrials.gov

Safety and Efficacy of HB-1 for Panic Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Panic Disorder
Interventions
DRUG

HB-01

HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

DRUG

Placebo

HB-1 matched placebo

Trial Locations (10)

10312

Richmond Behavioral Associates, Staten Island

11235

SPRI Clinical Trials, Brooklyn

32256

CNS Healthcare, Jacksonville

32801

CNS Healthcare, Orlando

38119

CNS Healthcare, Memphis

60640

Uptown Research Institute, Chicago

92845

Collaborative Neuroscience Research, Garden Grove

95124

Lumos Psychiatric Services, San Jose

06106

Institute of Living, Hartford

08009

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

Honeybrains Biotech LLC

INDUSTRY